Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle
Addex Therapeutics Ltd American Depositary Shares | FinOracle

Addex Therapeutics Ltd American Depositary Shares

Symbol: (NASDAQ:ADXN)

Addex Therapeutics Ltd is a biopharmaceutical company focused on the development of novel, orally available small molecule drugs to treat diseases of the central nervous system. The company’s lead product candidate, dipraglurant, is currently in clinical trials for the treatment of Parkinson’s disease and levodopa-induced dyskinesia.

Latest News

No Content Available

Welcome Back!

Login to your account below

Create New Account!

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.

Home
Trends
Premium
Favorite
Account
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?